Ward Jennifer A, McLellan Lauren, Stockley Martin, Gibson Karl R, Whitlock Gavin A, Knights Charlotte, Harrigan Jeanine A, Jacq Xavier, Tate Edward W
Department of Chemistry, Imperial College London , London, SW7 2AZ, United Kingdom.
MISSION Therapeutics, Ltd. , Moneta, Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom.
ACS Chem Biol. 2016 Dec 16;11(12):3268-3272. doi: 10.1021/acschembio.6b00766. Epub 2016 Oct 31.
Deubiquitinating enzymes play an important role in a plethora of therapeutically relevant processes and are emerging as pioneering drug targets. Herein, we present a novel probe, Ubiquitin Specific Protease (USP) inhibitor, alongside an alkyne-tagged activity-based probe analogue. Activity-based proteome profiling identified 12 USPs, including USP4, USP16, and USP33, as inhibitor targets using submicromolar probe concentrations. This represents the first intact cell activity-based profiling of deubiquitinating enzymes. Further analysis demonstrated functional inhibition of USP33 and identified a synergistic relationship in combination with ATR inhibition, consistent with USP4 inhibition.
去泛素化酶在众多与治疗相关的过程中发挥着重要作用,正逐渐成为开创性的药物靶点。在此,我们展示了一种新型探针,泛素特异性蛋白酶(USP)抑制剂,以及一种炔烃标记的基于活性的探针类似物。基于活性的蛋白质组分析使用亚微摩尔浓度的探针确定了12种USP,包括USP4、USP16和USP33作为抑制剂靶点。这代表了首次基于完整细胞活性的去泛素化酶分析。进一步分析证明了对USP33的功能抑制,并确定了与ATR抑制联合时的协同关系,这与USP4抑制一致。